ALB and liver disorder: Markers of liver synthesis were significantly higher in group 1 patients (median albumin value: 4.4 g/dL [IQR:4.2–4.6], p = 0.007, median total cholesterol level: 157.5 mg/dL [IQR: 130.5–182.5], p = 0.005) as well as the median platelet count (187.5 × 103/mm3 [IQR: 158.5–231.0], p = 0.0002), confirming a less advanced liver disease (median MELD: 7.0 [IQR: 6.0–7.0], p = 0.0001) and a lower stage of liver fibrosis (median FIB-4 score: 1.8 [IQR: 1.3–2.4], p = 0.0001, median APRI score: 0.3 [IQR: 0.2–0.4], p = 0.003).